Trials / Conditions / Conjunctivitis, Allergic

Conjunctivitis, Allergic

25 registered clinical trials studyying Conjunctivitis, Allergic — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	OJO-miR: microRNA Expression in Allergic Conjunctivitis. NCT07385495	Instituto de Oftalmología Fundación Conde de Valenciana	—
Not Yet Recruiting	Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy NCT07171307	Instituto de Oftalmología Fundación Conde de Valenciana	—
Unknown	Corneal Biomechanical Changes of Allergic Conjunctivitis NCT04299399	Zhongshan Ophthalmic Center, Sun Yat-sen University	—
Terminated	Topical rVA576 for Treatment of Atopic Keratoconjunctivitis NCT04037891	AKARI Therapeutics	Phase 1 / Phase 2
Completed	A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using NCT03709121	Aldeyra Therapeutics, Inc.	Phase 1 / Phase 2
Completed	Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children NCT06063044	Second Affiliated Hospital, School of Medicine, Zhejiang University	—
Unknown	Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis NCT03186755	Michael Marchand, MD	Phase 4
Completed	Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children NCT03375775	Karolinska Institutet	N/A
Completed	A Study of ADX-102 in Subjects With Allergic Conjunctivitis NCT03012165	Aldeyra Therapeutics, Inc.	Phase 2
Completed	Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Kor NCT02555761	Allergan	—
Completed	AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis NCT02161146	Allergan	Phase 3
Completed	AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis NCT02082262	Allergan	Phase 3
Completed	A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergi NCT01732757	Allergan	Phase 4
Completed	A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis NCT01470118	Allergan	Phase 4
Withdrawn	Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis NCT01541904	Laboratorios Sophia S.A de C.V.	Phase 2
Completed	Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis NCT01289431	Bausch & Lomb Incorporated	Phase 2
Completed	Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olop NCT01258309	Allergan	Phase 3
Completed	Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equival NCT00917488	Laboratorios Leti, S.L.	Phase 2
Completed	Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea NCT01987765	Allergan	—
Completed	Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Unit NCT00718744	Laboratorios Leti, S.L.	Phase 2
Completed	A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis NCT00655109	Greiner, Jack V., OD DO PhD	Phase 4
Completed	Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense NCT00501527	Laboratorios Leti, S.L.	Phase 2
Completed	Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic C NCT00424398	Bausch & Lomb Incorporated	Phase 2 / Phase 3
Completed	Twin SUBLIVAC® Grasses Clinical Efficacy Study NCT00422149	HAL Allergy	Phase 3
Completed	A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms ( NCT00311844	Organon and Co	Phase 4